Background: Resolvin D1 (RvD1) can play a determining role in inflammatory cell migration and reduce the expression of inflammatory cytokines to enhance cardioprotection. The aim of this study was to compare serum RvD1 levels in patients with ST-segment elevation myocardial infarction (STEMI) and individuals with normal coronary arteries (NCAs) and to evaluate the association between serum RvD1 levels and prognostic markers of STEMI. Methods: 140 subjects (88 patients diagnosed with the indication of STEMI and 52 healthy individuals with NCA) were studied. Results: Regression analysis revealed that RvD1 levels were independently associated with STEMI. While RvD1 levels were negatively correlated with high-sensitivity C-reactive protein, pro-brain natriuretic peptide, peak troponin, and Thrombolysis in Myocardial Infarction thrombus grade, they were positively correlated with left ventricular ejection fraction. An RvD1 cut-off value of 5.07 (ng/mL) was effective in predicting STEMI with a sensitivity of 79.5% and specificity of 96.2%. Conclusion: Serum RvD1 levels were found to be lower in the group with STEMI compared to the control group. Levels of RvD1 at admission were associated with poor prognostic markers of STEMI.

Background: A high thrombus burden has been connected with poor clinical events in patients with non-ST segment elevation myocardial infarction (NSTEMI). In patients with STEMI, a high MAPH score has been associated with a large thrombus burden. However, the predictive value of the MAPH score in determining the thrombus burden in patients with NSTEMI is unclear. The present report aimed to evaluate the prognostic role of the MAPH score in the estimating coronary thrombus burden in NSTEMI patients. The study patients were split into two groups according to their thrombus grade. The low shear rate (LSR) and high shear rate (HSR) were estimated by haematocrit levels and serum total protein levels. The MAPH score was calculated by adding mean platelet volume (MPV) levels and age, in addition to total protein and haematocrit. Results: The patients with a high thrombus burden (HTB) had a higher LSR, higher HSR and higher MAPH score compared to patients with low thrombus burden. MAPH score was found to be an independent predictors of HTB in Model 1 (OR: 1.124, 95% CI: 1.011–1.536; p = 0.039) and Model 2 (OR: 1.236; 95% CI: 1.002–1.525; p = 0.047). The cut-off value of the MAPH score for predicting HTB was 2 based on the Youden index. Conclusions: The MAPH score, which calculated by adding MPV levels and age, in addition to total protein and haematocrit, is a novel, easily accessible score. The MAPH score at both LSR and HSR was an independent predictor of HTB.

One of the oldest and most common methods of diagnosing heart abnormalities is auscultation. Even for experienced medical doctors, it is not an easy task to detect abnormal patterns in the heart sounds. Most digital stethoscopes are now capable of recording and transferring heart sounds. Moreover, it is proven that auscultation records can be classified as healthy or unhealthy via artificial intelligence techniques. In this work, an artificial intelligence-powered mobile application that works in a connectionless fashion is presented. According to the clinical experiments, the mobile application can detect heart abnormalities with approximately 92% accuracy, which is comparable to if not better than humans since only a small number of well-trained cardiologists can analyze auscultation records better than artificial intelligence. Using the diagnostic ability of artificial intelligence in a mobile application would change the classical way of auscultation for heart disease diagnosis.

Objectives: The endothelial activation and stress index (EASIX) has gained growing recognition as a potential marker for evaluating endothelial dysfunction and survival outcomes across diverse clinical conditions. This research aimed to assess the utility of the EASIX score in predicting disease severity and prognosis in patients diagnosed with acute pulmonary embolism (APE). Methods: A retrospective analysis was carried out on 364 consecutive patients diagnosed with APE at our hospital between 2022 and 2025. The cohort included 193 female (53%), with an average age of 64.8 ± 15.8 years. Based on clinical severity, patients were stratified into three categories: low-risk, intermediate-risk, and high-risk APE. Calculation of the EASIX score was performed using the following formula: lactate dehydrogenase (U/L) × serum creatinine (mg/dL)/platelet count (109/L). Results: Higher EASIX scores independently predicted both the high-risk APE and in-hospital mortality. Additionally, the EASIX score showed positive correlations with the simplified Pulmonary Embolism Severity Index (sPESI), troponin, and N-terminal pro-brain natriuretic peptide. Receiver operating characteristic (ROC) curve analysis identified an optimal EASIX cutoff value of 1.18 for predicting high-risk APE, offering a sensitivity of 77.5% and a specificity of 72.1%, with an area under the curve (AUC) of 0.816. Comparative ROC curve analysis revealed that the EASIX score (AUC = 0.835) exhibited a higher discriminative ability for in-hospital mortality compared to both the sPESI (AUC = 0.710) and Wells (AUC = 0.592) scores. Conclusion: The EASIX score appears to be a reliable and easily obtainable marker for assessing both disease severity and prognosis in APE.

Recent studies have shown a relation between red blood cell distribution width (RDW) / albumin (RAR) levels and worse outcomes in cases of pulmonary embolism (PE). Simplified pulmonary embolism severity index (sPESI) has been developed from more complex PESI score, predicting the risk of death in patients with acute PE (APE). This study aims to investigate whether RDW-Standard Deviation/Albumin (RDW-SD/Alb) can serve as a useful prognostic marker for APE and enhance the predictive capability of the sPESI. This research is a single-center, retrospective analysis involving patients over 18 years. We enrolled 235 consecutive hospitalized patients with confirmed APE diagnoses. To evaluate the sensitivity and specificity of RDW-SD/Alb, sPESI, and the combined sPESI plus RDW-SD/Alb in predicting 6-month all-cause death, we used Receiver Operating Characteristic (ROC) curves. Additionally, we conducted Kaplan–Meier analysis to assess the impact of elevated RDW-SD/Alb levels (> 13.6) on patient survival time. We utilized multivariate Cox regression analysis to identify independent prognostic factors affecting patients survival. The mortality rate for RDW-SD/Alb > 13.6 group was significantly higher than that for the RDW-SD/Alb ≤ 13.6 group. Area under ROC (AUROC) of sPESI plus RDW-SD/Alb was statistically larger than AUROC of sPESI (p = 0.025). In the fully adjusted model, increased RDW-SD/Alb levels were consistently linked to all-cause mortality within six months of admission. The predictive value of the sPESI for 6-month all-cause death improved when the RDW-SD/Alb > 13.6 parameter was included. RDW-SD/Alb, a novel inflammatory marker, was an independent prognostic factor for predicting 6-month all-cause mortality in patients with APE.